Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ MAGEB18 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA561161
Description
Immunogen sequence: STTNAIAPVS CSSNEGASSQ DEKSLGSSRE AEGWKEDPLN KKVVSLVHFL LQKYETKEPI T Highest antigen sequence identity to the following orthologs: Mouse - 38%, Rat - 41%.
The melanoma-associated antigen (MAGE) family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors and, based on their virtually exclusive tumor-specific expression in adult tissues, they have been used as targets for cancer immunotherapy. MAGE genes encode for tumor-rejection antigens that are expressed in tumors of different histologic types and in normal testis and placenta. MAGE-B18 (melanoma-associated antigen B18) is a 343 amino acid protein that contains one MAGE domain and may be involved in tumorigenesis. The gene encoding MAGE-B18 maps to human chromosome X, which contains nearly 153 million base pairs and houses over 1,000 genes.
Specifications
MAGEB18 | |
Polyclonal | |
Unconjugated | |
MAGEB18 | |
MAGBI; MAGE family member B18; MAGEB18; MAGE-B18 antigen; melanoma antigen family B, 18; melanoma antigen family B18; melanoma-associated antigen B18 | |
Rabbit | |
Antigen Affinity Chromatography | |
RUO | |
286514 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot | |
0.05 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q96M61 | |
MAGEB18 | |
Recombinant protein corresponding to Human MAGEB18. Recombinant protein control fragment (Product #RP-95711). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction